Tian Li1, Rui Providencia2, Nan Mu1, Yue Yin1, Mai Chen3, Yishi Wang1, Manling Liu1, Lu Yu4, Chunhu Gu5, Heng Ma6. 1. Department of Physiology and Pathophysiology, Fourth Military Medical University, No. 169 Changle West Rd, Xi'an, 710032, China. 2. Barts Heart Centre, St. Bartholomew's Hospital, London, UK. 3. Department of Cardiovascular Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. 4. Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. yulu@fmmu.edu.cn. 5. Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. guchunhu@fmmu.edu.cn. 6. Department of Physiology and Pathophysiology, Fourth Military Medical University, No. 169 Changle West Rd, Xi'an, 710032, China. hengma@fmmu.edu.cn.
Abstract
BACKGROUND: Metformin is a first-line drug in type 2 diabetes mellitus (T2DM) treatment, yet whether metformin may increase all-cause or cardiovascular mortality of T2DM patients remains inconclusive. METHODS: We searched PubMed and Embase for data extracted from inception to July 14, 2020, with a registration in PROSPERO (CRD42020177283). This study included randomized controlled trials (RCT) assessing the cardiovascular effects of metformin for T2DM. This study is followed by PRISMA and Cochrane guideline. Risk ratio (RR) with 95% CI was pooled across trials by a random-effects model. Primary outcomes include all-cause mortality and cardiovascular mortality. RESULTS: We identified 29 studies that randomly assigned patients with 371 all-cause and 227 cardiovascular death events. Compared with untreated T2DM patients, metformin-treated patients was not associated with lower risk of all-cause mortality (RR: 0.98; 95%CI: 0.69-1.38; P = 0.90), cardiovascular mortality (RR: 1.13; 95% CI: 0.60, 2.15; P = 0.70), macrovascular events (RR: 0.87; 95%CI: 0.70-1.07; P = 0.19), heart failure (RR: 1.02; 95% CI:0.61-1.71; P = 0.95), and microvascular events (RR: 0.78; 95% CI:0.54-1.13; P = 0.19). Combination of metformin with another hypoglycemic drug was associated with higher risk of all-cause mortality (RR: 1.49; 95% CI: 1.02, 2.16) and cardiovascular mortality (RR: 2.21; 95% CI: 1.22, 4.00) compared with hypoglycemic drug regimens with no metformin. CONCLUSION: The combination of metformin treatment may impose higher risk in all-cause and cardiovascular mortality. This finding, at least in part, shows no evidence for benefits of metformin in combination in terms of all-cause/cardiovascular mortality and cardiovascular events for T2DM. However, the conclusion shall be explained cautiously considering the limitations from UK Prospective Diabetes Study (UKPDS).
BACKGROUND:Metformin is a first-line drug in type 2 diabetes mellitus (T2DM) treatment, yet whether metformin may increase all-cause or cardiovascular mortality of T2DM patients remains inconclusive. METHODS: We searched PubMed and Embase for data extracted from inception to July 14, 2020, with a registration in PROSPERO (CRD42020177283). This study included randomized controlled trials (RCT) assessing the cardiovascular effects of metformin for T2DM. This study is followed by PRISMA and Cochrane guideline. Risk ratio (RR) with 95% CI was pooled across trials by a random-effects model. Primary outcomes include all-cause mortality and cardiovascular mortality. RESULTS: We identified 29 studies that randomly assigned patients with 371 all-cause and 227 cardiovascular death events. Compared with untreated T2DM patients, metformin-treated patients was not associated with lower risk of all-cause mortality (RR: 0.98; 95%CI: 0.69-1.38; P = 0.90), cardiovascular mortality (RR: 1.13; 95% CI: 0.60, 2.15; P = 0.70), macrovascular events (RR: 0.87; 95%CI: 0.70-1.07; P = 0.19), heart failure (RR: 1.02; 95% CI:0.61-1.71; P = 0.95), and microvascular events (RR: 0.78; 95% CI:0.54-1.13; P = 0.19). Combination of metformin with another hypoglycemic drug was associated with higher risk of all-cause mortality (RR: 1.49; 95% CI: 1.02, 2.16) and cardiovascular mortality (RR: 2.21; 95% CI: 1.22, 4.00) compared with hypoglycemic drug regimens with no metformin. CONCLUSION: The combination of metformin treatment may impose higher risk in all-cause and cardiovascular mortality. This finding, at least in part, shows no evidence for benefits of metformin in combination in terms of all-cause/cardiovascular mortality and cardiovascular events for T2DM. However, the conclusion shall be explained cautiously considering the limitations from UK Prospective Diabetes Study (UKPDS).
Authors: C S Kovacs; V Seshiah; R Swallow; R Jones; H Rattunde; H J Woerle; U C Broedl Journal: Diabetes Obes Metab Date: 2013-08-22 Impact factor: 6.577
Authors: Kirsti Hällsten; Kirsi A Virtanen; Fredrik Lönnqvist; Hannu Sipilä; Airi Oksanen; Tapio Viljanen; Tapani Rönnemaa; Jorma Viikari; Juhani Knuuti; Pirjo Nuutila Journal: Diabetes Date: 2002-12 Impact factor: 9.461
Authors: Reid H Whitlock; Ingrid Hougen; Paul Komenda; Claudio Rigatto; Kristin K Clemens; Navdeep Tangri Journal: Mayo Clin Proc Date: 2020-01 Impact factor: 7.616
Authors: Louise Lundby-Christensen; Lise Tarnow; Trine W Boesgaard; Søren S Lund; Niels Wiinberg; Hans Perrild; Thure Krarup; Ole Snorgaard; Birthe Gade-Rasmussen; Birger Thorsteinsson; Michael Røder; Elisabeth R Mathiesen; Tonny Jensen; Henrik Vestergaard; Christoffer Hedetoft; Leif Breum; Elsebeth Duun; Simone B Sneppen; Oluf Pedersen; Bianca Hemmingsen; Bendix Carstensen; Sten Madsbad; Christian Gluud; Jørn Wetterslev; Allan Vaag; Thomas P Almdal Journal: BMJ Open Date: 2016-02-25 Impact factor: 2.692